1. Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer
   Ye Tao et al, 2023, Frontiers in Oncology CrossRef
2. Association of Baseline Tumor-Specific Neoantigens and CD8+ T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors
   Csaba Kerepesi et al, 2024, JCO Precision Oncology CrossRef
3. Retrospective study of the combination of TP and PF regimens with or without immune checkpoint inhibitors for the first-line treatment of locally advanced or advanced esophageal squamous cell carcinoma
   Zhengfeng Zhang et al, 2023, Therapeutic Advances in Medical Oncology CrossRef